
Sign up to save your podcasts
Or


In this episode, we are joined by two lymphoma experts - Victoria Nachar, PharmD, BCOP and Tycel Phillips MD - to discuss the use of bispecific antibodies in Diffuse Large B-Cell Lymphoma (DLBCL)! Stay tuned for an exciting episode where we discuss the data, their possible role in therapy, and what questions and controversies remain.
Relevant Articles:
Review on Design of Bispecifics - https://pubmed.ncbi.nlm.nih.gov/25728220/
Epcoritamab - https://pubmed.ncbi.nlm.nih.gov/36548927/
Glofitamab - https://pubmed.ncbi.nlm.nih.gov/36507690/
Mosunetuzumab - https://pubmed.ncbi.nlm.nih.gov/34914545/
Odronextamab - https://pubmed.ncbi.nlm.nih.gov/35366963/
CRS and ICANS grading - https://pubmed.ncbi.nlm.nih.gov/30592986/
By Bernard Marini, Anthony Perissinotti, et al.4.5
3030 ratings
In this episode, we are joined by two lymphoma experts - Victoria Nachar, PharmD, BCOP and Tycel Phillips MD - to discuss the use of bispecific antibodies in Diffuse Large B-Cell Lymphoma (DLBCL)! Stay tuned for an exciting episode where we discuss the data, their possible role in therapy, and what questions and controversies remain.
Relevant Articles:
Review on Design of Bispecifics - https://pubmed.ncbi.nlm.nih.gov/25728220/
Epcoritamab - https://pubmed.ncbi.nlm.nih.gov/36548927/
Glofitamab - https://pubmed.ncbi.nlm.nih.gov/36507690/
Mosunetuzumab - https://pubmed.ncbi.nlm.nih.gov/34914545/
Odronextamab - https://pubmed.ncbi.nlm.nih.gov/35366963/
CRS and ICANS grading - https://pubmed.ncbi.nlm.nih.gov/30592986/

38,482 Listeners

26,040 Listeners

88,023 Listeners

113,446 Listeners

56,951 Listeners

187 Listeners

10,331 Listeners

7,237 Listeners

53 Listeners

8 Listeners

16,543 Listeners

10,983 Listeners

51 Listeners

196 Listeners

737 Listeners